GIP
LGND icon

Granite Investment Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Granite Investment Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.8M Sell
54,155
-3,771
-7% -$746K 0.66% 43
2025
Q4 		$11M Sell
57,926
-3,694
-6% -$710K 0.65% 50
2025
Q3 		$10.9M Sell
61,620
-62,842
-50% -$9.34M 0.62% 56
2025
Q2 		$14.1M Sell
124,462
-8,667
-7% -$926K 0.69% 52
2025
Q1 		$14M Buy
133,129
+17,591
+15% +$1.99M 0.71% 51
2024
Q4 		$12.4M Sell
115,538
-2,463
-2% -$278K 0.54% 65
2024
Q3 		$11.8M Buy
+118,001
New +$11.9M 0.51% 73
2021
Q1 		– Sell
-59,173
Closed -$3.67M – 283
2020
Q4 		$3.67M Sell
59,173
-96,578
-62% -$5.51M 0.13% 149
2020
Q3 		$9.26M Sell
155,751
-165,500
-52% -$11.3M 0.41% 95
2020
Q2 		$22.4M Buy
321,251
+264,766
+469% +$16.8M 1.08% 25
2020
Q1 		$2.56M Buy
56,485
+18,298
+48% +$1.04M 0.17% 135
2019
Q4 		$2.48M Buy
38,187
+14,217
+59% +$950K 0.12% 179
2019
Q3 		$1.49M Sell
23,970
-160
-0.7% -$10K 0.08% 194
2019
Q2 		$1.72M Sell
24,130
-69,437
-74% -$5.11M 0.09% 167
2019
Q1 		$7.34M Buy
93,567
+85,823
+1,108% +$6.5M 0.42% 86
2018
Q4 		$656K Buy
+7,744
New +$826K 0.05% 221
2018
Q2 		– Sell
-132,459
Closed -$13.6M – 326
2018
Q1 		$13.6M Sell
132,459
-3,152
-2% -$312K 0.91% 40
2017
Q4 		$11.6M Sell
135,611
-52,575
-28% -$4.56M 0.73% 60
2017
Q3 		$16M Buy
188,186
+9,570
+5% +$758K 0.99% 27
2017
Q2 		$13.5M Buy
178,616
+15,209
+9% +$1.06M 0.91% 31
2017
Q1 		$10.8M Buy
163,407
+33,057
+25% +$2.17M 0.74% 54
2016
Q4 		$8.26M Sell
130,350
-5,307
-4% -$335K 0.61% 74
2016
Q3 		$8.64M Buy
135,657
+21,166
+18% +$1.55M 0.64% 63
2016
Q2 		$8.52M Buy
114,491
+25,092
+28% +$1.86M 0.67% 51
2016
Q1 		$5.97M Sell
89,399
-419
-0.5% -$25.5K 0.54% 65
2015
Q4 		$6.08M Buy
+89,818
New +$5.55M 0.55% 76

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Granite Investment Partners's LGND Position: Q1 2026 in Review

Granite Investment Partners reduced its Ligand Pharmaceuticals (LGND) stake by 6.5% in Q1 2026, selling an estimated $746K and leaving 54,155 shares worth $10.8M. The position accounts for 0.66% of the portfolio, ranked #43.

Granite Investment Partners first reported a position in LGND in Q4 2015 and has held it in 26 quarters since. The position peaked at $22.4M in Q2 2020. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Granite Investment Partners held 54,155 shares of Ligand Pharmaceuticals worth $10.8M as of Q1 2026.
  • Granite Investment Partners sold 3,771 Ligand Pharmaceuticals shares in Q1 2026, an estimated $746K.
  • Ligand Pharmaceuticals made up 0.66% of Granite Investment Partners's portfolio in Q1 2026, its #43 holding.
  • Granite Investment Partners first reported a position in Ligand Pharmaceuticals in Q4 2015 and has held it in 26 quarters since.
  • Granite Investment Partners's Ligand Pharmaceuticals position peaked at $22.4M in Q2 2020.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Granite Investment Partners's 13F filing for Q1 2026, filed 30 Apr 2026.